X

ASCPT Awards

Certara


Each year, ASCPT's Awards program provides an array of awards that recognize outstanding science and achievement in clinical pharmacology and translational science. ASCPT's awards span the continuum of clinical pharmacology, translational science, and therapeutics. The array of awards is designed to recognize every turning point in the career path from young investigator to seasoned scientist with the focus on exceptional achievements in the dimensions that the awards are focused.  
 
Submit your nomination!

Click here to view the list of the 2024 award recipients.
The Gary Neil Prize for Innovation in Drug Development was established in 2004 to honor the memory of Gary Neil, PhD. Dr. Neil, a former leader of worldwide Research and Development at Wyeth-Ayerst, was a pioneer in the field of drug development. Dr. Neil was instrumental in creating a highly effective drug development and strategic decision-making structure at Alza through his roles as CEO and President of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals Corporation. Dr. Neil had a significant role as a member of the boards of directors of Pharsight Corporation, Geron Corporation, Calydon and several other biotech companies. 

The goal of the Gary Neil Prize for Innovation in Drug Development is to stimulate the application of innovative science to clinical drug development by recognizing outstanding individuals or teams who have been leaders in this area. Click here to see the award history and criteria.

Eligibility 
Individuals as well as teams who have demonstrated leadership in the application of significant, innovative science to clinical drug development. The award is open to individuals from all clinical pharmacology employment sectors. 

Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation 
The Gary Neil Prize for Innovation in Drug Development will be presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $2,500 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 
The Leon I. Goldberg Early Investigator Award was established in 1986 to honor a young scientist for accomplishments in the field of clinical pharmacology achieved early in his/her career. 

The goal of the Leon I. Goldberg Early Investigator Award is to encourage and recognize these scientists active in the field of clinical pharmacology. Click here to see the award history and criteria. 

Eligibility 
The nominee can be an academic, industrial, or regulatory scientist who has made a substantial contribution to clinical pharmacology within 10 years of the completion of an advanced degree and/or a post-doctoral fellowship or residency program. An important aspect is that the recipient will be able to deliver an engaging presentation about the impact of their research. 

The award is intended to foster the candidate’s potential for significant contributions to the future of clinical pharmacology.

There are no restrictions concerning the scientific field in which nominees have earned their doctoral degrees. Although it is encouraged, a nominee need not be a member of the Society. 

Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation 
The Leon I. Goldberg Early Investigator Award is presented at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the work that forms the basis of the award. In addition, the recipient of the award will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration are reimbursed by the Society.
The Oscar B. Hunter Career Award in Therapeutics was established in 1955 to honor individual scientists for outstanding contributions to clinical pharmacology and therapeutics. This award recognizes a meritorious career in drug research, excellence or contributions in direct patient care, and a distinguished teaching career. The Oscar B. Hunter Career Award in Therapeutics is the Society's premier award. The goal of the award is to honor a scientist for outstanding contributions to clinical pharmacology and therapeutics over the individual's professional life. Click here to see the award history and criteria.

Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate’s work has fostered an environment of inclusion and/or has had a demonstrable impact on people in underrepresented populations. 

Eligibility 
The nominee can be an academic, industrial, or regulatory scientist who has demonstrated a sustained record of lifelong contributions to clinical pharmacology and dissemination of knowledge who will be able to give an engaging presentation about their career and the impact of their work.  

The nominee must be a well-recognized leader in clinical pharmacology, but does not need to be an ASCPT member.

Prize and Presentation 
The Oscar B. Hunter Career Award in Therapeutics is presented at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the works that form the basis of the award. In addition, the recipient of the award will receive a bronze medal mounted on a plaque and a $1,500 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society.
The Rawls-Palmer Progress in Medicine Award was established in 1978 by Dr. W. B. Rawls to further his commitment to continuing medical education and its impact on patient care. This award was founded through the generosity of the late Dr. and Mrs. W.B. Rawls, and honors the memory of their parents. 

The goal of the Rawls-Palmer Progress in Medicine Award is to incorporate the efforts of modern research in patient care and to help bridge the gap between the results of research and its application in patient care. Click here to see the award history and criteria.

Eligibility 
A nominee can be an academic, industrial, or regulatory scientist who is widely recognized for their transformational and/or translational discoveries or innovative approaches impacting clinical pharmacology research and clinical practice. A nominee does not need to be an ASCPT member.

Diversity, Equity, and Inclusion 
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation 
The Rawls-Palmer Progress in Medicine Award is presented at the ASCPT Annual Meeting. The recipient will present a lecture focusing on recent developments in clinical pharmacology. In addition, the recipient will receive a $1,000 prize and a plaque. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 
The Sheiner-Beal Pharmacometrics Award has been established as an ASCPT Award by the Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco (UCSF) to acknowledge the pioneering contributions of Drs. Lewis B. Sheiner and Stuart Beal to the scientific discipline of pharmacometrics. 

Definition 
Pharmacometrics is defined as the science that quantifies drug, disease and clinical trial information to aid efficient drug development, regulatory decisions, and rational therapeutic decision making in patients. It uses models that are generally based on pharmacology, physiology, genetic constitution, and/or disease for quantitative analysis of interactions between drugs and patients. The domain of pharmacometrics includes the application of techniques that address the interactions between pharmacokinetics, pharmacodynamics, pharmacogenomics, and disease progression with a focus on populations and variability in the exposure-response relationship.

Goal 
The goal of the Sheiner-Beal Pharmacometrics Award is to recognize outstanding achievements at the forefront of research or leadership in pharmacometrics and/or application of pharmacometric concepts and techniques to enhance research, development, regulatory evaluation, and/or utilization of therapeutic products. Click here to see the award history and criteria.

Eligibility 
The candidate must be an investigator or leader who is actively advancing the scientific discipline of pharmacometrics and/or its impact on research, development, regulatory evaluation, or utilization of therapeutic products, and is capable of delivering an engaging and comprehensive lecture on pharmacometrics. The award is intended to recognize clinical pharmacologists, clinician scientists, computational scientists, statisticians, and others in academia, industry, government agencies, or consulting whose work falls within the scope of the definition of pharmacometrics.

Diversity, Equity, and Inclusion 
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation
The Sheiner-Beal Pharmacometrics Award will be presented annually at the ASCPT Annual Meeting. The recipient will present a lecture summarizing the works that form the basis of the award. In addition, the recipient will receive a $1,500 prize and a plaque. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 
The Henry W. Elliott Distinguished Service Award was established in 1979 to recognize an ASCPT member who has gone above and beyond the call of duty in service to the organization. 

The goal of the Henry W. Elliott Distinguished Service Award is to acknowledge outstanding efforts on behalf of the organization by an individual member and in doing so, encourage other ASCPT members to contribute their time and talent to the Society. Click here to see the award history and criteria.

Eligibility 
A nominee must be a member of ASCPT. Past Board members who have been off of the Board for at least one year at the time of nomination are eligible to be nominated. The essential criterion is documented evidence of excellent service to the organization. One or two outstanding acts of service or a long record of many acts of service may justify the award. The recipient should have a record of continuous service to the Society, including one or many major accomplishments. 

Diversity, Equity, and Inclusion 
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate’s service-based leadership has fostered a diverse and inclusive environment at ASCPT.
 

Prize and Presentation 
The Henry W. Elliott Distinguished Service Award is presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 
The William B. Abrams Award in Geriatric Clinical Pharmacology was established with support from the Merck Company Foundation in 1996 to honor an investigator in geriatric clinical pharmacology for outstanding contributions to the field. 

Dr. Abrams, a Past President of ASCPT, had a long and illustrious career in the pharmaceutical industry, mostly at the Merck Research Laboratories. Among his many accomplishments in geriatric clinical pharmacology, he was the founding Co-Editor of the Merck Manual of Geriatrics, created the Scientific Section on Geriatric Clinical Pharmacology of ASCPT, and developed and funded post-doctoral training programs in geriatric clinical pharmacology. 

Dr. Abrams' objective in establishing this award was to encourage more young scientists to enter the field of geriatric clinical pharmacology by recognizing accomplishments in the field at the Society's Annual Meeting. Click here to see the award history and criteria.

Eligibility 
A nominee must be an investigator in geriatrics who is actively involved in high-quality teaching and research in geriatric clinical pharmacology.

Diversity, Equity, and Inclusion 
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.
 
Prize and Presentation 
The William B. Abrams Award in Geriatric Clinical Pharmacology is presented at the ASCPT Annual Meeting. The recipient will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society.
The Malle Jurima-Romet Mid-Career Leadership Award was established in 2017 to honor Malle Jurima-Romet, PhD, the Senior Director, Drug Development at Celerion. With over 25 years of biomedical and pharmaceutical research experience, Dr. Jurima-Romet was a devoted scientist and outstanding leader in her field. Because of Dr. Jurima-Romet’s thoughtful guidance and leadership she had an unmistakable impact on drug development, her staff and colleagues thrived, and the organizations she contributed her skills to, including the American Society for Clinical Pharmacology and Therapeutics, where she served on the Scientific Program Committee and on the Board of Directors, benefitted. Along with her devotion to clinical pharmacology, Dr. Jurima-Romet was passionate about art, most notably as a painter and as a master at Ikebana, the art of Japanese flower arranging. The combination of science and art made Dr. Jurima-Romet a unique and talented scientist whose leadership and achievements will have a lasting impact on clinical pharmacology.

Goal:
The Malle Jurima-Romet Mid-Career Leadership Award will honor the legacy of  Dr. Jurima-Romet by recognizing exceptional leadership and outstanding contributions to clinical pharmacology by a mid-career clinical pharmacologist and encourage continued leadership and future impactful scientific contributions to clinical pharmacology. Click here to see the awards history and criteria.

Eligibility
The nominees should be recognized leaders in their field who have reached their mid-career, defined as at least 10 years post-specialty training. The nominee must be able to provide evidence of exceptional and ongoing leadership, excellent scientific achievements in their particular area of practice and a commitment to the future of clinical pharmacology and translational medicine. The nominee may practice clinical pharmacology in an academic, industrial, government, or consulting setting.

Criteria
The nominees must provide evidence of four or more of the following:
  1. Mentorship – The nominee actively serves as a role model or mentor who shows dedication to the development and advancement of future leaders in the field of clinical pharmacology and therapeutics.
  2. Team Building  – The nominee demonstrates a commitment to team building, values and respects the contributions of team members, has the ability to engage all parties and allows all involved to share ownership in achievements.
  3. Professional Growth – The nominee shows a commitment to professional development and encourages professional development in others.
  4. Leadership Roles – The nominee holds positions that effectively promote and advance the field of clinical pharmacology and therapeutics and is recognized as a leader among peers.
  5. Service to the Society – The nominee demonstrates exemplary volunteer contributions to the American Society for Clinical Pharmacology and Therapeutics.  
  6. Initiative – The nominee demonstrates initiative and goes above and beyond the standard measures to achieve a successful outcome.  
Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.
The Darrell Abernethy Early Stage Investigator Award is intended to foster the growth of early career scientists. This award honors the memory of Darrell Abernethy, MD, PhD, who was a leader in clinical pharmacology and a devoted advocate for discipline of clinical pharmacology. During his career, Darrell was a successful mentor to hundreds of mentees and it was his wish that any award be dedicated to helping young faculty succeed in the area of investigative clinical pharmacology. Click here to see the award history and criteria.

Eligibility:
The applicant is an ASCPT member who must have completed a graduate degree and is a junior faculty member working toward obtaining a senior faculty position within clinical pharmacology or translational medicine at the time of grant award. The applicant must be a US/Canadian citizen or a permanent resident of the US. The applicant must show evidence of heading up an independent research laboratory or of being an early stage investigator with promise for a successful career and indicate the percentage of time to be committed to research during the award period, with the expectation being at least 60%.

Applications should include the following:
  • A cover letter briefly summarizing the applicant’s qualifications and a description of the ongoing or proposed research.
  • Applicant’s curriculum vitae.
  • The names of 3 potential scientific or career mentors.
  • No more than 5 pages that describe the project, inclusive of a summary/abstract, specific aims, and the research strategy as well as a section on the protection of human subjects, if applicable.
  • Two letters of recommendation, with one letter from the candidate’s Division Chief, Department Chair, or Dean demonstrating support of the candidate and the second from someone outside the candidate’s institution.
  • An electronic copy of one of the applicant’s publications that they consider their best work.
Diversity, Equity, and Inclusion:
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Selection Process:
The ASCPT Award Selections Task Force will select the recipient based on the following criteria:
  • Qualifications and track record of the candidate
  • Potential impact of the work
  • Environment and institutional support for the work
Additional considerations:
  • Recipient will be provided with an ASCPT member mentor (scientific or career mentor).
  • Recipient is encouraged to submit their research for presentation at the ASCPT Annual Meeting as either an oral or poster presentation.
  • The recipient will be formally recognized at the ASCPT Annual Meeting and will be provided with complimentary registration to attend the award presentation.
Prize and Presentation
The Darrell Abernethy Early Stage Investigator Award will receive a grant for a one-year period, January 1, 2025 – December 31, 2025, for the total amount of $10,000. The Grant funds are directed to the sponsoring institution and may provide salary support, supplies, equipment, travel, and other expenses necessary for the pursuit of the recipient’s research project. Funds may not be used for administrative overhead costs.
 
The ASCPT Mentor Award was established in 2011 by the ASCPT Education Committee. A mentor is one of the most influential figures in the life of a student/trainee in the field of pharmacology and translational medicine. This award will recognize an ASCPT member who serves in a mentoring role, making a significant impact in the career of the mentee, and contributes to the retention of young members. Click here to see the award history and criteria.

Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation
The ASCPT Mentor Award recipient will be recognized during the ASCPT Annual Meeting and will be presented a token of recognition.
The Dolores Shockley Diversity and Inclusion in Clinical Research Award was named in honor of Dr. Dolores Shockley, the first Black woman to receive a PhD in pharmacology in the United States and the first Black woman to chair a pharmacology department in the United States. The goal of this award is to recognize individuals who contribute to greater diversity and inclusion practices in clinical research, so all potential patient populations benefit from the research. Click here to see the award history and criteria.

Eligibility
The nominee is eligible if they have made a substantial contribution to incorporation of clinical pharmacology and translational science tools to increase the diversity of individuals included in clinical research and/or increase the generalizability of research findings to typically underrepresented or underserved communities. The recipient is expected to deliver an engaging presentation on their work and its impact, with particular emphasis on its relevance to diversity, inclusion, and/or equity. The recipient does not need to be a member of ASCPT.

  Diversity, Equity, and Inclusion
ASCPT is committed to recognizing and promoting excellence in research, collaborations, and efforts that highlight dimensions of diversity. Nominators should address how the candidate has fostered a diverse and inclusive environment.

Prize and Presentation
The Dolores Shockley Diversity and Inclusion in Clinical Research Award is presented at the ASCPT Annual Meeting. The recipient is expected to deliver an engaging presentation on their work and its impact, with particular emphasis on its relevance to diversity, inclusion, and/or equity. The recipient will receive a plaque and a $1,000 prize. Travel expenses, hotel expenses, and meeting registration will be reimbursed by the Society. 
The William B. Abrams Lecture is a joint educational initiative of ASCPT and the FDA. The lecture series, supported in part by The Merck Company Foundation, was established in 1999 to honor William B. Abrams, MD, an ASCPT president from 1975 to 1976.

Among his many accomplishments, Dr. Abrams worked at the FDA as the first special government employee to establish the Center for Drug Evaluation and Research Staff College and develop its curriculum. He also had a distinguished career in the pharmaceutical industry as a longtime employee of Merck Research Laboratories.

For more than 10 years, ASCPT and the FDA have invited experts from academia, industry, and government to discuss advances in clinical pharmacology and drug development. These scientists have excelled in their specialty areas and are some of the most highly esteemed clinical pharmacologists in the field. Their presentations convey novel information and perspectives on fundamental aspects of clinical pharmacology. Previous lectures have included speakers from the Mayo Clinic, University of California, Children's Mercy Hospitals and Clinics, and the National Institutes of Health. Click here for information about this year's award.

*Please note that ASCPT does not accept nominations for the ASCPT FDA William B. Abrams Award. This award is selected by CASE at FDA.
*At the discretion of the Scientific Awards Selection Task Force, and with majority support of its members, an award nominee may be re-purposed to a different award.
 
  • Instructions for Nominators
  • Nomination FAQ
  • Letter of Recommendation Guidelines
*All nominators must be ASCPT members.
  1. Before nominating a candidate for an award, please visit the corresponding webpages below to familiarize yourself with the specific award criteria and the history of award recipients.  Please note current Board Members and members of the Awards Selection Task Force are ineligible for awards. Past Board Members who have been off the Board for at least one year at the time of nomination are eligible for awards. 
Who can nominate a person for an award?
To submit an award nomination, access the submission site. Only ASCPT members are able to submit award nominations.  Past Board members who have been off of the Board for at least one year at the time of nomination are eligible for awards.

Can I nominate someone for the ASCPT-FDA Abrams Award?
ASCPT does not accept nominations for the ASCPT-FDA Abrams Award. The Award recipient is selected by CASE at FDA.

What should my nomination packet include?
The nomination package should include:
  1. The nominator(s) assessment (max length 5 pages), a comprehensive evaluation of all aspects of the candidate’s outstanding attributes that qualify them for the specific award. It is strongly recommended to include specific examples of how the candidate meets or exceeds the award criteria. ASCPT encourages a single assessment signed by multiple co-signers. 
  2. The candidate’s CV (max length 25 pages), highlighting in particular the scientific accomplishments and qualifications for the award; or in the case of the Henry W. Elliott Distinguished Service Award, the candidate’s extraordinary commitment of time and talent to ASCPT. 
*The nomination package should not include copies of publications or other copyrighted or protected intellectual property. 

**If nominating or applying for the Darrell Abernethy Early Stage Investigator Award, please see additional instructions here and submit the documents listed below:
  • A cover letter from the nominee briefly summarizing the applicant's qualifications and a description of ongoing/proposed research. Please suggest the names of 3 potential scientific or career mentors.
  • Applicant's curriculum vitae.
  • No more than 5 pages that describe the Project. Suggested format and page lengths are Summary/Abstract (1/2 - 1 page), Specific Aims (1 page), and the Research Strategy (limit 2 pages) and additionally, a section on the protection of human subjects (no limit) if appropriate.
  • Two letters of recommendation, with one letter from the candidate's Division Chief, Department Chair, or Dean demonstrating support of the candidate and the second from someone outside the candidate's institution. 
  • Copy of one of the applicant's publications that he/she consider his/her best work.
Which sectors of clinical pharmacology practice are appropriate for nomination?
The nominee’s sector of clinical pharmacology practice is comprehensive; the nominee can include an international academic (e.g., basic or clinical research), industrial (e.g., big/small PHARMA, BIOTECH, CROs, consulting), or regulatory scientist, with various types of accomplishments that signify the candidate’s outstanding science. 

What types of accomplishments would qualify a person for an award?
Publications in highly impactful scientific journals are key examples that point to substantial accomplishment; but publications are neither mandatory nor the exclusive evidence of such accomplishment. It is the responsibility of the nominator to provide adequate detail about documented evidence and public information and aspects of the candidate’s specific accomplishments that unequivocally warrant the recognition of the award. This may include the description of materials such as (but not limited to):
  • Publications
  • Patents
  • Inventions
  • Methodologies
  • New drug applications
  • Individual influence on drug discovery
  • Drug development and regulatory decisions,
  • Process changes
  • Other products of clinical pharmacology rendering scientific excellence
The letter of recommendation should:
  • Convey the impact of the candidate’s scientific contribution from the perspective of the author(s) of the letter and discuss how the candidate meets or exceeds the criteria for the award. 
  • Document the recognition of a candidate’s outstanding science (or service for the Henry W. Elliott Distinguished Service Award) by including examples that are derived from sources inside and outside the candidate’s own institution.
*A streamlined letter of recommendation may be written by a group of individuals (particularly when they have a unique informed perspective of the candidate’s accomplishments) providing a composite perspective of the candidate’s accomplishments to which each of the co-authors testifies by their signature on the letter. 
 

Questions

If you have any questions about any of the awards or nomination procedures, please email meetings@ascpt.org or (703) 836-6981, ext. 109.

 

 

 

Photo Gallery
Recent News
Contact Us